Idioma:

The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience

Moningi, Shalini ; Dholakia, Avani S. ; Raman, Siva P. ; Blackford, Amanda ; Cameron, John L. ; Le, Dung T. ; De Jesus-Acosta, Ana M. C. ; Hacker-Prietz, Amy ; Rosati, Lauren M. ; Assadi, Ryan K. ; Dipasquale, Shirl ; Pawlik, Timothy M. ; Zheng, Lei ; Weiss, Matthew J. ; Laheru, Daniel A. ; Wolfgang, Christopher L. ; Herman, Joseph M.

Annals of surgical oncology, 2015-07, Vol.22 (7), p.2352-2358 [Periódico revisado por pares]

New York: Springer US

Texto completo disponível

Citações Citado por

Enviar para

Título:
The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience
Autor: Moningi, Shalini ; Dholakia, Avani S. ; Raman, Siva P. ; Blackford, Amanda ; Cameron, John L. ; Le, Dung T. ; De Jesus-Acosta, Ana M. C. ; Hacker-Prietz, Amy ; Rosati, Lauren M. ; Assadi, Ryan K. ; Dipasquale, Shirl ; Pawlik, Timothy M. ; Zheng, Lei ; Weiss, Matthew J. ; Laheru, Daniel A. ; Wolfgang, Christopher L. ; Herman, Joseph M.
Assuntos: Adenocarcinoma - mortality ; Adenocarcinoma - pathology ; Adenocarcinoma - surgery ; Adult ; Aged ; Aged, 80 and over ; Dose Fractionation ; Female ; Follow-Up Studies ; Gastrointestinal Oncology ; Humans ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Staging ; Oncology ; Pancreatic cancer ; Pancreatic Neoplasms - mortality ; Pancreatic Neoplasms - pathology ; Pancreatic Neoplasms - surgery ; Prognosis ; Prospective Studies ; Radiosurgery - mortality ; Retrospective Studies ; Surgery ; Surgical Oncology ; Survival Rate
É parte de: Annals of surgical oncology, 2015-07, Vol.22 (7), p.2352-2358
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Background Stereotactic body radiation therapy (SBRT) is a promising option for patients with pancreatic cancer (PCA); however, limited data support its efficacy. This study reviews our institutional experience of SBRT in the treatment of locally advanced (LAPC) and borderline resectable (BRPC) PCA. Methods Charts of all PCA patients receiving SBRT at our institution from 2010 to 2014 were reviewed. Most patients received pre-SBRT chemotherapy. Primary endpoints included overall survival (OS) and local progression-free survival (LPFS). Patients received a total dose of 25–33 Gy in five fractions. Results A total of 88 patients were included in the analysis, 74 with LAPC and 14 with BRPC. The median age at diagnosis was 67.2 years, and median follow-up from date of diagnosis for LAPC and BRPC patients was 14.5 and 10.3 months, respectively. Median OS from date of diagnosis was 18.4 months (LAPC, 18.4 mo; BRPC, 14.4 mo) and median PFS was 9.8 months (95 % CI 8.0–12.3). Acute toxicity was minimal with only three patients (3.4 %) experiencing acute grade ≥3 toxicity. Late grade ≥2 gastrointestinal toxicity was seen in five patients (5.7 %). Of the 19 patients (21.6 %) who underwent surgery, 79 % were LAPC patients and 84 % had margin-negative resections. Conclusions Chemotherapy followed by SBRT in patients with LAPC and BRPC resulted in minimal acute and late toxicity. A large proportion of patients underwent surgical resection despite limited radiographic response to therapy. Further refinements in the integration of chemotherapy, SBRT, and surgery might offer additional advancements toward optimizing patient outcomes.
Editor: New York: Springer US
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience

New York: Springer US

Buscando em bases de dados remotas. Favor aguardar.